Injectable is worth exploring
2020 Mar 27;2(1):58-61
note that daily dosing is only for the activation phase of the GLOW protocol (weeks 1-4) , decreasing to 5x per week for the remodeling phase (weeks 5-8), and further reduced to 2-3x per week during maintenance (weeks 9-12)
Retatrutide's Phase 2a in MASH/MASLD (Sanyal et al., Nat Med 2024) reported approximately 86% relative reduction in liver fat content at 12 mg/week the strongest hepatic-fat data among the incretin class

Epithalon as a tool to study pharmacological modulation of the Hayflick limit Chronobiology and the pineal-hypothalamic axis melatonin secretion profile, expression of circadian clock genes (Bmal1, Per, Cry), models of rhythm desynchronization in aging Geroprotection in rodent models survival parameters, oxidative stress markers, incidence of cancer in long-term cohorts (Anisimovs line of research) Profile peptide geroprotectors comparison of Epithalon with other short regulatory peptides of the bioregulation school in terms of impact on aging markers Models of regulatory gene expression research on the proposed epigenetic mechanism of action of short peptides Summary Epithalon (AEDG, Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed by Vladimir Chawinson as a standardized analogue of epithalamine pineal gland extract
The FDA has noted both the lack of human clinical trial data and uncertainty about long-term safety